• Novelstem International posted a net loss of $55,021 for quarter ended March 31, 2026, narrowing from $207,216 a year earlier.
• Operating loss tightened to $4,953 as general and administrative costs fell to $4,953, down from $94,574.
• Interest expense declined to $50,068 from $112,642, primarily due to settlement of litigation funding agreement on May 9, 2025.
• Current assets rose to about $101,000, while current liabilities eased to $2.05 million; company reported no revenue and said primary asset is its right to monetization of former NewStem license now held by Yissum.
• Liquidity included $250,000 raised in private common-stock issuance on March 13, 2026, while net cash used in operating activities was about $139,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novelstem International Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023227), on May 15, 2026, and is solely responsible for the information contained therein.